| |
| |
|
| Insider
Information: |
Karbe Frank |
| Relationship: |
|
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
882,302 |
|
|
Indirect Shares
|
11,849 |
|
|
| Direct
Value |
$7,811,180 |
|
|
|
Indirect Value
|
$259,849 |
|
|
| Total
Shares |
894,151 |
|
|
| Total
Value |
$8,071,029 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
3
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-3.0
|
-3.0
|
| Percentage
Gain/Loss : |
 -82.8%
|
-4.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Exelixis Inc |
EXEL |
EVP and CFO |
2014-02-15 |
93,990 |
2014-02-15 |
11,849 |
Premium* |
|
|
Tekmira Pharmaceuticals Corp |
TKMR |
Director |
2015-01-01 |
5,000 |
|
0 |
Premium* |
|
|
Myovant Sciences Ltd. |
MYOV |
Principal Finl & Accou... |
2021-07-07 |
212,296 |
2019-06-11 |
0 |
Premium* |
|
|
Better Therapeutics |
BTTX |
|
2023-12-18 |
526,516 |
2022-09-15 |
0 |
Premium* |
|
|
Phathom Pharmaceuticals, Inc. |
PHAT |
|
2024-05-29 |
44,500 |
2023-05-25 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-12-15 |
4 |
OE |
$5.11 |
$5,366 |
D/D |
1,050 |
164,520 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-11-30 |
4 |
OE |
$5.11 |
$7,665 |
D/D |
1,500 |
164,970 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-11-30 |
4 |
AS |
$24.00 |
$36,000 |
D/D |
(1,500) |
163,470 |
0 |
% |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2011-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
73,803 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2011-08-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
75,756 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2011-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
78,316 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2012-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
80,269 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2012-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
76,123 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2012-08-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
77,360 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2012-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
81,467 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2013-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
82,704 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2013-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
90,030 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2013-08-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
91,248 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2013-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,953 |
93,626 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2014-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,954 |
94,847 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2021-07-07 |
4 |
S |
$21.75 |
$70,296 |
D/D |
(3,232) |
212,296 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-08-28 |
4 |
AS |
$20.04 |
$73,146 |
D/D |
(3,650) |
163,470 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2020-08-28 |
4 |
OE |
$5.11 |
$18,652 |
D/D |
3,650 |
167,120 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP and CFO |
• – – |
2012-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,099) |
74,170 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP, CFO |
• – – |
2008-10-31 |
4 |
B |
$3.30 |
$25,250 |
D/D |
7,500 |
31,340 |
2.74 |
- |
|
| EXEL |
Exelixis Inc |
Executive VP and CFO |
• – – |
2011-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,813 |
67,923 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Principal Finl & Accounting |
• – – |
2019-06-11 |
4 |
B |
$9.10 |
$72,800 |
D/D |
8,000 |
8,000 |
2.74 |
- |
|
| PHAT |
Phathom Pharmaceuticals, ... |
Director |
– • – |
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP, CFO |
• – – |
2008-10-30 |
4 |
B |
$3.20 |
$32,125 |
D/D |
10,000 |
23,840 |
2.74 |
- |
|
| PHAT |
Phathom Pharmaceuticals, ... |
|
– • – |
2024-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
19,500 |
0 |
- |
|
65 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
